[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

[PTC Therapeutics, Inc.](/topic/$ptct)

### Top Social Posts

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$PTCT Stock PTC Therapeutics (PTCT $65.95) entered a monthly bullish trend. Expect an Uptrend continuation $REGN $INCY $EXEL $MRNA $ARWR $BCRX $ADPT $SRPT $NVAX $NKTR"  
[X Link](https://x.com/Tickeron/status/1979604888712860136) [@Tickeron](/creator/x/Tickeron) 2025-10-18T17:45Z 19.4K followers, XXX engagements


"Strong growth but not overvalued . $PTCT $AGI $VCTR $SMCI $SUPN $VRTX $MNSO and $CTRA are showing up in our selection"  
[X Link](https://x.com/ChartMill/status/1978581651463540908) [@ChartMill](/creator/x/ChartMill) 2025-10-15T22:00Z 11.2K followers, XXX engagements


"Huntingtons Disease Clinical Research Congress 2025 Day X Discussion about clinical trials in progress from $QURE $PTCT & Roche"  
[X Link](https://x.com/DesertDweller93/status/1978557465575805153) [@DesertDweller93](/creator/x/DesertDweller93) 2025-10-15T20:23Z 3868 followers, 5111 engagements


"Seven commercial in vivo gene therapies for rare diseases: Luxturna (RPE65-LCA2; $RRHBY) Zolgensma (SMA; $NVS) Kebilidi (AADC deficiency; $PTCT) Roctavian (HemA; $BMRN) Hemgenix (HemB; $QURE) and Elevidys (DMD; $SRPT) using AAV vectors and Vykuvek (DEB; $KRYS) using Herpesvirus. Zolgensma is a blockbuster ($1bn+ net sales/year). Elevidys was on-track to become one (strong demand) despite all the issues associated with systemic gene therapy. Luxturna has had strong demand but so few patients that the commercial case has been very challenging. Vyjuvek did $300M in revenues the first full-year"  
[X Link](https://x.com/GerardCaelles/status/1978550460983197811) [@GerardCaelles](/creator/x/GerardCaelles) 2025-10-15T19:56Z 1099 followers, XXX engagements